Augustas Pivoriunas

Dr. Augustas Pivoriunas

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2015 in Cytotherapy
Verified
Journal Article
Closed access
AJAkvilė Jarmalavičiūtė
Akvilė Jarmalavičiūtė
VTVirginijus Tunaitis
Virginijus Tunaitis
UPUgnė Pivoraitė
Ugnė Pivoraitė
AVAlgirdas Venalis
Algirdas Venalis
APAugustas Pivoriunas
Augustas Pivoriunas

1 February 2019 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
KNKarīna Narbute
Karīna Narbute
VPVladimirs Pilipenko
Vladimirs Pilipenko
JPJolanta Pupure
Jolanta Pupure
ZDZane Dzirkale
Zane Dzirkale
UJUgnė Jonavičė
Ugnė Jonavičė
APAugustas Pivoriunas
Augustas Pivoriunas
Parkinson's disease (PD) is the second most common neurodegenerative disorder affecting millions of people worldwide. At present, there is no effective cure for PD, treatments are symptomatic and do not halt progression of neurodegeneration. Extracellular vesicles (EVs) can cross the blood–brain barrier and represent promising alternative to the classical treatment strategies. In the present study, we examined therapeutic effects of intranasal administration of EVs derived from human exfoliated deciduous teeth stem cells (SHEDs) on unilateral 6‐hydroxydopamine (6‐OHDA) medial forebrain bundle (MFB) rat model of PD. CatWalk gait tests revealed that EVs effectively suppressed 6‐OHDA‐induced gait impairments. All tested gait parameters (stand, stride length, step cycle and duty cycle) were significantly improved in EV‐treated animals when compared with 6‐OHDA‐lesion group rats. Furthermore, EVs slowed down numbers of 6‐OHDA‐induced contralateral rotations in apomorphine test. Improvements in motor function correlated with normalization of tyrosine hydroxylase expression in the striatum and substantia nigra. In conclusion, we demonstrated, for the first time, the therapeutic efficacy of intranasal administration of EVs derived from SHEDs in a rat model of PD induced by 6‐OHDA intra‐MFB lesion. Our findings could be potentially exploited for the development of new treatment strategies against PD. Stem Cells Translational Medicine 2019

Verified
Journal Article
Open access
PDF file
PAPavle Andjus
Pavle Andjus
MKMaja Kosanović
Maja Kosanović
Katarina MilicevicKatarina Milicevic
Katarina Milicevic
MGMukesh Gautam
Mukesh Gautam
Seppo VainioSeppo Vainio
Seppo Vainio
Barbara ZavanBarbara Zavan
Barbara Zavan
Extracellular vesicles (EVs) have recently attracted a great deal of interest as they may represent a new biosignaling paradigm. According to the mode of biogenesis, size and composition, two broad categories of EVs have been described, exosomes and microvesicles. EVs have been shown to carry cargoes of signaling proteins, RNA species, DNA and lipids. Once released, their content is selectively taken up by near or distant target cells, influencing their behavior. Exosomes are involved in cell–cell communication in a wide range of embryonic developmental processes and in fetal–maternal communication. In the present review, an outline of the role of EVs in neural development, regeneration and diseases is presented. EVs can act as regulators of normal homeostasis, but they can also promote either neuroinflammation/degeneration or tissue repair in pathological conditions, depending on their content. Since EV molecular cargo constitutes a representation of the origin cell status, EVs can be exploited in the diagnosis of several diseases. Due to their capability to cross the blood–brain barrier (BBB), EVs not only have been suggested for the diagnosis of central nervous system disorders by means of minimally invasive procedures, i.e., “liquid biopsies”, but they are also considered attractive tools for targeted drug delivery across the BBB. From the therapeutic perspective, mesenchymal stem cells (MSCs) represent one of the most promising sources of EVs. In particular, the neuroprotective properties of MSCs derived from the dental pulp are here discussed.

1 November 2016 in Pharmacological Research
Verified
Journal Article
Closed access
AJAkvilė Jarmalavičiūtė
Akvilė Jarmalavičiūtė
APAugustas Pivoriunas
Augustas Pivoriunas

7 May 2021 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
APAugustas Pivoriunas
Augustas Pivoriunas
Alexei VerkhratskyAlexei Verkhratsky
Alexei Verkhratsky

24 April 2015 in Inflammation
Verified
Journal Article
Closed access
PDF file
UPUgnė Pivoraitė
Ugnė Pivoraitė
AJAkvilė Jarmalavičiūtė
Akvilė Jarmalavičiūtė
VTVirginijus Tunaitis
Virginijus Tunaitis
GRGiedrė Ramanauskaitė
Giedrė Ramanauskaitė
AVAida Vaitkuvienė
Aida Vaitkuvienė
APAugustas Pivoriunas
Augustas Pivoriunas